Clinical trial Recruiting at 1 site Interventional Ages 18 to 65

Fully implanted wireless brain-computer interface to replace upper limbs in tetraplegia

Official title: A Prospective, Multicenter, Single-Arm Target Value Clinical Trial to Evaluate the Efficacy and Safety of Implantable Brain-Computer Interface Hand Motor Function Compensation System for Upper-Limb Functional Replacement in Tetraplegic Patients With Spinal Cord Injury

Run by NeuroXess Technology (shanghai) Co.,Ltd. · NCT07720882 · Data updated 2026-11-12

This study tests a fully implanted brain-computer interface to help people with tetraplegia from spinal cord injury regain hand and arm function.

Quick facts

Study typeInterventional
Ages18 Years to 65 Years
SexAll
Enrollment32 (estimated)
SponsorNeuroXess Technology (shanghai) Co.,Ltd.
Industry-sponsored
Locations1 site (Shanghai, Shanghai Municipality)
StatusRecruiting
StartedJuly 7, 2026
Main results expectedJanuary 30, 2027
Study endsApril 30, 2027
Registry record updatedJuly 22, 2026
Trial IDNCT07720882 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18–65 with cervical spinal cord injury (C2–C6), ASIA A–C, substantial hand impairment, intact motor cortical function, stable condition for at least 6 months, and adequate cognitive function.

Probably not a fit

Individuals without preserved brain motor areas, unstable neurological status, or insufficient cognitive function may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective, multicenter, single-arm study will implant an eligible brain-computer interface to restore upper-limb function in adults with tetraplegia due to cervical spinal cord injury. After implantation, participants will undergo standardized brain-computer training, including brain-controlled pneumatic gloves, with follow-up visits at 1, 2, 3, and 6 months to assess safety and functional outcomes. The trial uses a target-value design to evaluate the device’s potential to provide functional replacement for impaired upper limbs. All enrolled subjects receive the same intervention and assessments to determine feasibility and clinical benefit. The study is sponsored by NeuroXess Technology (Shanghai) Co., Ltd., with Huashan Hospital as a collaborating site.

Why it matters

Potential benefit: If successful, the device could enable meaningful improvement in hand and arm function for people with tetraplegia.

How similar studies have gone: Prior studies of brain-computer interfaces for motor restoration have shown feasibility and safety signals in related populations, supporting further evaluation this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* 18 years ≤ age ≤ 65 years, male or female;
* Cervical spinal cord injury (injury level C2-C6), with ASIA Impairment Scale grade A, B, or C;
* Severe impairment of hand function on the target upper extremity: finger flexor muscle strength \< grade 3 as assessed by the ISNCSCI scale;
* ARAT score ≥ 2 for "hand to mouth"; score ≥ 1 for both "hand to top of head" and "hand to back of head"; and scores ≤ 1 for each of the grasp, grip, and pinch tasks;
* Neurological assessment confirms normal motor-related cortical function of the brain, with no acute cerebral functional changes;
* At least 12 months have elapsed since the cervical spinal cord injury resulting in tetraplegia, and the condition has been stable for at least 6 months following standardized treatment (with documentation of rehabilitation therapy records available);
* Good cognitive function: Mini-Mental State Examination (MMSE) score ≥ 22 and Montreal Cognitive Assessment (MoCA) score ≥ 26 ;
* Possess the basic visual, auditory, and language comprehension abilities required for interaction, and be able to cooperate with training;
* The subject voluntarily participates and is willing to comply with the relevant examinations and follow-up visits.

Exclusion Criteria:

* Neurodegenerative diseases / secondary injury due to tumors, or severe autonomic dysreflexia;
* Presence of intracranial lesions or contraindications to intracranial implantation: active epilepsy or definite epileptogenic tendency; severe cerebrovascular disease; brain tumor; moderate-to-severe sequelae of traumatic brain injury; space-occupying lesions or structural abnormalities at the electrode implantation target area; already implanted with active implantable electronic devices such as cardiac pacemakers/defibrillators, cochlear implants, deep brain stimulators, or drug infusion pumps, or presence of local metal foreign bodies/implants in the area to be implanted; or other contraindications to intracranial implantation as assessed by the investigator;
* Malignancies in other organ systems;
* Cardiovascular system diseases: severe cardiac insufficiency, severe arrhythmias, or uncontrolled hypertension;
* Other ongoing medical interventions that may affect the benefit from BCI intervention (e.g., dependence on ventilator support, tracheostomy, nasogastric tube feeding, etc.);
* Presence of psychiatric or psychological disorders that may interfere with the subject's participation in BCI training, such as depression (HAMD ≥ 18 points) or anxiety disorder (HAMA ≥ 14 points) ;
* Presence of active infection; severe coagulation abnormalities (activated partial thromboplastin time (APTT) or prothrombin time (PT) \> 2.5 × upper limit of normal); or other severe systemic diseases that, as assessed by the investigator, may significantly increase surgical risk or interfere with neurological function assessment or system use;
* Contraindications to surgery or anesthesia, or deemed unsuitable for implantation surgery by anesthesiology/surgical assessment;
* Fever, or vital signs and/or intracranial status not yet stabilized;
* Upper-limb motor dysfunction due to other etiologies, such as amyotrophic lateral sclerosis, syringomyelia, spinal vascular diseases, muscular dystrophy, hypokalemic periodic paralysis, spondylitis, arthritis, osteomyelitis, peripheral nerve injury, tendon rupture, etc.;
* Planned MRI examination during the device implantation period;
* Life expectancy \< 6 months (e.g., severe end-stage diseases);
* Participation in other drug or medical device clinical trials within the past 1 month;
* Pregnant or breastfeeding women;
* Other conditions that, in the investigator's judgment, make the subject unsuitable for participation in this clinical trial.

Where it's running

  • Huashan Hospital
    Shanghai, Shanghai Municipality, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.